• Viral RIPK3 Degradation and Inflammation

  2026-08-11

  Liu et al. identified a cowpox virus and orthopoxvirus factor that hijacks the host SCF machinery to ubiquitinate and degrade RIPK3, thereby suppressing necroptosis. Genetic gain- and loss-of-function experiments in viruses and mice show that this mechanism reshapes viral replication, inflammation, and pathogenicity.

• ARCA Cy5 EGFP mRNA (5-moUTP) Workflow

  2026-08-10

  Build a two-channel workflow that separates mRNA uptake from productive translation in mammalian cells. The same fluorescent reporter supports microscopy, flow cytometry, formulation comparisons, and immune-cell delivery studies without secondary RNA staining.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-09

  FITC-Concanavalin A (ConA) Conjugate provides a fluorescence-based approach for detecting accessible α-D-glucose and α-D-mannose residues on cell-surface glycoconjugates. It is suited to immunofluorescence staining and flow cytometry carbohydrate-probe workflows, but not to non-glycan targets or protocols that disregard its light, temperature, and divalent-ion requirements.

• LARP7–STING Signaling in Diabetic Cardiomyopathy

  2026-08-08

  The reference study identifies LARP7 as a regulator of glucose-induced diabetic cardiomyopathy by linking its cytoplasmic translocation to impaired STING degradation through the autophagy–lysosomal pathway. Genetic and pharmacological experiments in mice and neonatal cardiomyocytes suggest that targeting LARP7 or STING may reduce cardiac dysfunction, apoptosis, and fibrosis, although translation beyond the experimental model remains unproven.

• TET2 Metabolite Binding: Protocol and Findings

  2026-08-07

  This STAR Protocols study presents an orthogonal workflow that combines a flow cytometry-based TET2 activity assay with saturation transfer difference NMR to validate metabolite binding and functional regulation. The approach distinguishes TET2 activators from inhibitors and provides a practical framework for connecting metabolic state with epigenetic enzyme activity.

• Mc-Val-Cit-PABC-PNP: Practical Guide for ADC Peptide Linker

  2026-08-07

  Mc-Val-Cit-PABC-PNP addresses the need for a cathepsin B-cleavable peptide linker in antibody-drug conjugate (ADC) synthesis, ensuring selective lysosomal payload release. It is best employed in organic solvent-based workflows and is unsuitable for aqueous, diagnostic, or therapeutic applications.

• Lycorine Targets ALDH3A1 and FAO to Inhibit Pancreatic Cance

  2026-08-06

  This study identifies lycorine as a potent inhibitor of pancreatic cancer cell growth by targeting ALDH3A1 and disrupting fatty acid oxidation. Utilizing transcriptomic profiling, functional assays, and in vivo validation, the work provides mechanistic insights and a foundation for targeted therapy research.

• Cy3 TSA Fluorescence Kit: Quantitative Mapping of Tumor Lipo

  2026-08-06

  Discover how the Cy3 TSA Fluorescence System Kit enables quantitative, high-resolution mapping of de novo lipogenesis in cancer cells. This article explores advances in signal amplification and practical assay choices, offering a unique perspective for researchers seeking to detect low-abundance biomolecules.

• Leonurine Disrupts Endothelial STING Pathway in Doxorubicin

  2026-08-05

  This study uncovers that cardiac vascular endothelial cells (CVECs) are primary sensors and amplifiers of doxorubicin-induced cardiotoxicity via the cGAS-STING/NF-κB/NLRP3 inflammasome axis. Leonurine, a natural alkaloid, is identified as a direct and selective STING inhibitor, offering a paradigm shift by targeting upstream endothelial signaling to prevent cardiomyopathy.

• Ionomycin Free Acid: Optimizing Calcium Ionophore Workflows

  2026-08-05

  Ionomycin free acid empowers researchers to precisely modulate intracellular calcium, unlocking advanced cell signaling, oocyte activation, and cancer pathway dissection. This guide translates the latest TNBC/FAK research into stepwise protocols, troubleshooting strategies, and actionable insights for maximizing experimental reproducibility.

• 15-PGDH Inhibition Enhances Muscle Repair During GLP-1RA The

  2026-08-04

  This study reveals that 15-PGDH inhibition markedly improves muscle stem cell function and regenerative myofiber growth in the context of semaglutide-induced weight loss. These findings offer mechanistic insight and practical direction for researchers aiming to preserve skeletal muscle integrity during anti-obesity therapy.

• Necrostatin-1: RIP1 Kinase Inhibitor for Advanced Necroptosi

  2026-08-04

  Necrostatin-1 is the gold-standard RIP1 kinase inhibitor for dissecting necroptosis and inflammation in both cell and animal models. Its robust selectivity, data-backed efficacy, and workflow versatility make it indispensable for studying RIP1-mediated cell death and acute tissue injury.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Study Insights

  2026-08-03

  A recent study demonstrates that homoharringtonine, a cytotoxic alkaloid with established use in leukemia research, can clear SARS-CoV-2 from the upper respiratory tract within days. This work highlights homoharringtonine's potential as a first-line antiviral strategy for future coronavirus outbreaks, offering broad implications for translational virology.

• Applied Use Cases of Sodium Picosulfate in Gut–Brain Axis Mo

  2026-08-03

  Sodium Picosulfate from APExBIO enables researchers to bridge gut motility, electrolyte modulation, and neuroinflammation in both in vitro and in vivo models. This guide details stepwise workflows, protocol enhancements, and troubleshooting tips tailored for chronic constipation and gut–liver–brain axis research.

• Humanized Mice and Species-Specific PK of Ester Prodrug HD56

  2026-08-02

  This study demonstrates that humanized liver mice are essential for accurately modeling the pharmacokinetics and metabolism of carboxylate ester prodrugs, such as HD56, by closely replicating human-specific biotransformation. These findings refine predictive tools for translational drug development and highlight the limitations of conventional animal models in preclinical research.

548 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page